[{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Alendronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Urology","graph2":"Phase I","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Yuyu Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ticlopidine","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuyu Pharma \/ Yuyu Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Yuyu Pharma \/ Yuyu Pharma"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Dermatology","graph2":"Preclinical","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"YY-162","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"YY-162","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"YY-201","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yuyu Pharma \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Yuyu Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : YP-P10 is a novel, patented, synthetic peptide with anti-inflammatory properties, which reduces Th17 cells and is being explored for the potential treatment of dry eye disease (DED).

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          April 27, 2023

                          Lead Product(s) : YP-P10

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Dutasteride inhibits both Type I and Type II 5-alpha reductase which act to transform testosterone, a male hormone, into a DHT hormone. In scientific studies, excess DHT is understood to be the cause of hair loss.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 29, 2022

                          Lead Product(s) : Dutasteride

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Preclinical data show that YP-P10 was a more active immunomodulator than lifitegrast in lowering pro-inflammatory cytokines and chemokines production in human peripheral blood mononuclear cells (PBMCs) when stimulated by lipopolysaccharide (LPS)

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          November 03, 2022

                          Lead Product(s) : YP-P10

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : YP-P10 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          July 20, 2022

                          Lead Product(s) : YP-P10

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : YP-P10, opthalmic solution, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties to treat patients with dry eye disease (DED).

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          July 20, 2022

                          Lead Product(s) : YP-P10

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : YY-201 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 07, 2017

                          Lead Product(s) : YY-201

                          Therapeutic Area : Urology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tadalafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 20, 2016

                          Lead Product(s) : Tadalafil

                          Therapeutic Area : Urology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Ticlopidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carotid Stenosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 08, 2014

                          Lead Product(s) : Ticlopidine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Recipient : Samsung Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : YY-162 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Mental Disorders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 20, 2012

                          Lead Product(s) : YY-162

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Alendronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoporosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 03, 2012

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank